2026-05-18 · Dugan Margaret (Chief Medical Officer) · OTHER
2026-05-18 · Lennon David James (CHIEF EXECUTIVE OFFICER) · OTHER
2026-05-18 · Giacobello Scott M. (CHIEF FINANCIAL OFFICER) · OTHER
2026-05-18 · BALL BRYAN (See remarks) · OTHER
2026-05-18 · Castelein Caley (Director) · OTHER
INSTITUTIONAL OWNERSHIP
Institutional holders83
Shares held45,219,550
Value$201.55M
Percent of shares outstanding79.32%
As of quarter end2026-06-30
RECENT NEWS
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
WHWK: Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026